Cell/Gene Tx channel feed

NeuEx­cell heads east, land­ing sub­ur­ban Philly head­quar­ters

4 years ago
Manufacturing

Af­fimed spurs promis­ing re­sponse num­bers in NK cell study, but dura­bil­i­ty will be the big ques­tion

4 years ago
R&D

Blue­bird bio may fi­nal­ly get a gene ther­a­py ap­proved in the US

4 years ago
R&D

Stem cell spe­cial­ist Ncar­dia bags new funds to help scale man­u­fac­tur­ing ops

4 years ago
Manufacturing

WuXi of­fi­cial­ly opens cell and gene ther­a­py site in Philly; An­oth­er mas­sive man­u­fac­tur­ing site comes to NC

4 years ago
News Briefing
Manufacturing

Gilead goes all in on its Ar­cus al­liance, pay­ing $725M cash for rights to a slate of can­cer drugs. And there's no room for fail­ure

4 years ago
Deals

FDA+ roundup: ALS bill would pro­vide $100M an­nu­al­ly to ac­cess po­ten­tial drugs; FDA needs to bet­ter en­force Clin­i­cal­Tri­als.gov re­port­ing, re­searchers say

4 years ago
FDA+

At­las, New­path throw $125M be­hind a new ap­proach to gene edit­ing from the field’s biggest names

4 years ago

Ex­clu­sive: Big-name aca­d­e­mics and in­vestors are qui­et­ly prepar­ing a slate of new (epi)genome edit­ing com­pa­nies

4 years ago
In Focus

CRISPR, Vi­a­Cyte beat Ver­tex to the clin­ic with di­a­betes cell ther­a­py that evades the im­mune sys­tem

4 years ago
R&D

As­traZeneca, Mod­er­na start to raise the cur­tain on a new mR­NA heart drug — but ef­fi­ca­cy will have to wait

4 years ago
R&D

The renowned drug hunter, the Wash­ing­ton in­sid­er, the MIT strate­gist: How did one low-pro­file biotech en­list a dream team of top biotech ad­vi­sors?

4 years ago
Bioregnum

On the heels of sol­id tu­mor da­ta and with com­peti­tors surg­ing, Po­sei­da scraps au­tol­o­gous CAR-T in fa­vor of al­lo

4 years ago
R&D

Im­mat­ics un­veils promis­ing, ear­ly-stage da­ta for a top con­tender in the race to de­vel­op TCRs. Now it has to live up to ex­pec­ta­tions

4 years ago
R&D

Feng Zhang’s qui­et spin­out snares $215M in a race for the next big CRISPR com­pa­ny

4 years ago
Financing

'We were wrong': Af­ter ush­er­ing Mer­ck KGaA in­to PD-(L)1 fren­zy, on­col­o­gy chief jumps on mis­sion to 'tur­bocharge' T cells

4 years ago
Financing

John Maraganore steps in­to a new role at an up­start biotech as the god­fa­ther phase of his ca­reer takes shape

4 years ago
Bioregnum

They had promis­ing gene ther­a­pies for their daugh­ter's ul­tra-rare dis­ease. But how to tell if one worked?

4 years ago
In Focus

Black­stone dou­bles down on cell ther­a­py, pour­ing life (and a lot of cash) in­to a once hot biotech

4 years ago
Deals

FDA push­es back de­ci­sion on J&J, Leg­end's BC­MA CAR-T

4 years ago
FDA+

Pfiz­er, No­var­tis, Janssen and oth­er biotechs sign on­to NIH/FDA pro­gram to de­vel­op new gene ther­a­pies for rare dis­eases

4 years ago
FDA+

No­var­tis dumps AveX­is pro­gram for Rett syn­drome af­ter fail­ing re­peat round of pre­clin­i­cal test­ing

4 years ago
R&D

Jen­nifer Doud­na spin­out inks a Mam­moth CRISPR deal with Ver­tex worth near­ly $700M

4 years ago
Deals

Sim­mer­ing feud be­tween blue­bird and a ri­val con­tin­ues with al­le­ga­tions of patent fraud

4 years ago
Pharma
First page Previous page 34353637383940 Next page Last page
A service from the Financial Times